

## Removed Sections

## Key Artifacts

- Investment Heat Map
- Revenue Heat Map
- Patent Heat Map
- Dynamic Patent Dashboard
- Taxonomy Sample
- Patent Search Strategy
- Clinical Timeline Visualization
- Patent Product Mapping
- Stent Landscape-Flash
- Company Profile - Flash

## Technological insights

The ideal ureteric stent biomaterial is yet to be discovered. Ongoing research with respect to material modifications and stent designs has achieved better patient comfort, and decreased stent-related complications. Drug-eluting stent technology is an interesting development which may prevent infection, encrustation and other stent related symptoms.

## Reimbursements

<sup>2</sup> "Allowed Amount" is the amount Medicare determines to be the maximum allowance for any Medicare covered procedure. Actual payment will vary based on the maximum allowance less any applicable deductibles, co-insurance, etc.

<sup>3</sup> The hospital outpatient payment rates are 2011 Medicare national averages. Source: November 2, 2010 Federal Register, CMS-1504-FC.

<sup>4</sup> The ASC payments rates are 2011 Medicare national averages. ASC rates are from the 2011 Ambulatory Surgical Center Covered Procedures List ? Addendum AA. Source: November 2, 2010 Federal Register, CMS-1504-FC.